A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

Histologically confirmed, locally advanced, not amenable to curative therapy, or metastatic NSCLC
ALK-rearrangement confirmed by the Food and Drug Administration (FDA) approved test
NSCLC that has failed crizotinib treatment
Measurable disease as defined by RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (<=) 2
Adequate hematologic, hepatic and renal function

Exclusion Criteria:

Prior therapy with ALK inhibitor other than crizotinib
Brain or leptomeningeal metastases that are symptomatic and/or requiring treatment
History of serious cardiac dysfunction
History of or current active infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
Clinically significant gastrointestinal abnormality that would affect absorption of the drug
Pregnant or lactating women